CINV Treatment Market: Is "Medical Cannabis" Becoming a Mainstream Antiemetic in 2026? A defining 2026 industry trend is the rapid legitimization and growth of the "Cannabinoid" segment within the CINV treatment space. In 2026, cannabinoids are recognized as the fastest-growing drug class in the market, as more clinicians prescribe them for "refractory CINV"—cases where traditional medications have failed. This 2026 shift is supported by evolving legal landscapes and new...